Related Experiment Video
Updated: Jul 31, 2025
14:20
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.8K
Using quantitative single molecule localization microscopy to optimize multivalent HER2-targeting ligands
Devin L Wakefield1, Ottavia Golfetto1, Raphael Jorand1
1Department of Cancer Biology and Molecular Medicine, Beckman Research Institute, Duarte, CA, United States.
Frontiers in Medicine
|May 4, 2023
Summary
Combining trastuzumab and pertuzumab antibodies enhances HER2 receptor clustering in breast cancer cells. This approach, using advanced protein engineering, shows promise for developing novel HER2-targeted therapies.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- HER2-positive metastatic breast cancer treatment often involves targeting the HER2 receptor.
- Trastuzumab and pertuzumab are monoclonal antibodies that target HER2 but have distinct mechanisms.
- The combination of trastuzumab and pertuzumab improves progression-free survival in patients.
Purpose of the Study:
- To investigate the molecular mechanisms underlying the efficacy of combined HER2-targeted antibodies.
- To assess and optimize the clustering of HER2 receptors using protein engineering and quantitative single molecule localization microscopy (qSMLM).
- To evaluate the impact of antibody-mediated HER2 clustering on downstream signaling pathways.
Main Methods:
- Utilized quantitative single molecule localization microscopy (qSMLM) to visualize and quantify HER2 clustering in breast cancer cells.
- Engineered multivalent ligands, including meditope technology, to enhance HER2 receptor aggregation.
- Assessed the effects of different antibody formats (monovalent Fab, individual mAbs, mAb combinations, multivalent ligands) on HER2 organization.
- Measured the inhibition of epidermal growth factor (EGF)-dependent downstream kinase activation.
Main Results:
- Individual antibodies (trastuzumab or pertuzumab) significantly increased HER2 clustering compared to a monovalent Fab fragment.
- The combination of trastuzumab and pertuzumab induced the highest level of HER2 clustering.
- Engineered multivalent ligands, in combination with trastuzumab, further enhanced HER2 clustering.
- Meditope-based combinations showed greater early inhibition of EGF-dependent kinase activation compared to trastuzumab plus pertuzumab.
Conclusions:
- Monoclonal antibodies (mAbs) and multivalent ligands can effectively modulate HER2 receptor organization and activation.
- Enhanced HER2 clustering by therapeutic agents may represent a key mechanism for improved treatment efficacy.
- The developed approach holds potential for the future design of novel HER2-targeted cancer therapeutics.
